Lin Shui Ke Cheng Xiaofen Li Pixian Shui Shuangshuang Li Yang Peng Jian Li Fengzhu Guo Cheng Yi Dan Cao
10.3389/fimmu.2020.01127
Front Immunol
2020 Jun 19;11:1127.
pd-1 inhibitor case report chemotherapy combination therapy durable response good tolerance metastatic pancreatic ductal adenocarcinoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/32636837/
Antineoplastic Combined Chemotherapy Protocols / administration & dosage Carcinoma, Pancreatic Ductal / drug therapy Pancreatic Neoplasms / drug therapy
Antineoplastic Combined Chemotherapy Protocols / administration & dosage Carcinoma, Pancreatic Ductal / drug therapy Pancreatic Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Albumins / administration & dosage Antibodies, Monoclonal, Humanized / administration & dosage B7-H1 Antigen / metabolism Carcinoma, Pancreatic Ductal / metabolism Carcinoma, Pancreatic Ductal / secondary Deoxycytidine / administration & dosage Deoxycytidine / analogs & derivatives Gemcitabine Humans Immune Checkpoint Inhibitors / administration & dosage Immunohistochemistry Male Middle Aged Paclitaxel / administration & dosage Pancreatic Neoplasms / metabolism Pancreatic Neoplasms / pathology Tomography, X-Ray Computed Treatment Outcome 130-nm albumin-bound paclitaxel Albumins Antibodies, Monoclonal, Humanized B7-H1 Antigen CD274 protein, human Immune Checkpoint Inhibitors Deoxycytidine toripalimab Paclitaxel Gemcitabine
PMC7318868
32636837
Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
2020